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Abstract 
This study examines the extent to which managed care behavioral controls are associated with 
treatment intensity in outpatient substance abuse treatment facilities. Data are from the 1995 
NationaI Drug Abuse Treatment System Survey, a nationally representative survey that includes over 
600provider organizations with a response rate of 86%. Treatment intensity is measured in three 
ways: (1) the number of months clients spend in outpatient drug treatment, (2) the number of  
individual treatment sessions clients receive over the course of treatment, and (3) the number of 
group treatment sessions clients receive over the course of treatment. After accounting for selection 
bias and controlling for market, organization, and client characteristics, there is no significant 
relationship between the scope of managed care oversight and treatment intensity. However, the 
stringency of  managed care oversight activities is negatively associated with the number of 
individual and group treatment sessions received over the course of treatment. 
Introduction 
Managed behavioral care programs have the potential to dramatically alter mental health and 
substance abuse treatment practices by influencing the practice patterns of providers within the 
defined network, l*z There has been rapid growth of managed care in this sector over the past decade. 
It is estimated that by the end of 1999, the mental health and substance abuse benefits of nearly 177 
million people were included in managed behavioral care programs, a 23% increase from the 
previous year. 3 In the public sector, many Medicaid programs also are implementing managed care 
programs for mental health and substance abuse conditions. 4 As managed care becomes more 
prevalent in behavioral health, there is increasing interest in whether or not and how this form of 
financing and delivery affects treatment practices: In particular, concern has been expressed about 
whether managed care, with its emphasis on cost control, affects the intensity of substance abuse 
treatment. Drug treatment intensity encompasses both the length of time clients spend in treatment 
and the amount or number of visits received during treatment. 
Substance abuse treatment intensity is important for several reasons. First, longer treatment is the 
most important predictor of various post-treatment outcomes, including reduced drug use, fewer 
arrests, improved employment outcomes, and fewer subsequent readmissions. A recent exhaustive 
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literature review revealed that this association holds for clients with a wide range of addiction 
problems receiving treatment in every substance abuse treatment modality. 6-1~ Further, the number 
of sessions of drug treatment received during treatment is consistently found to improve abstinence 
and other important treatment outcomes. 14-18 Last, in their efforts to reduce the costs of behavioral 
health services, managed care firms may specifically limit treatment intensity through benefit 
package design, utilization review, and other oversight activities. 19 
Surprisingly, little is known about the impact of managed care on substance abuse treatment. 19 
There have been relatively few studies of the effects of managed behavioral care on substance abuse 
treatment providers, 2°-z6 and few comprehensive studies focus specifically on managed care activities 
and effects in outpatient settings, the predominant form of substance abuse treatment. 27 This research 
builds on the authors' previous work in the area of managed care and substance abuse treatment in 
the following ways. First, the effects of two dimensions of managed care oversight that were 
developed in previous research 23,25 are empirically tested in the current study. Second, the authors' 
previous research :5,26 examined the effects of managed care on two organizational phenomena: 
administrative burden and technical efficiency. Based on their prior findings, the authors now extend the 
conceptual model and examine managed care's effects on treatment intensity for the first time. The 
specific aim of this study is to fill the gaps in previous research by providing a comprehensive, national 
examination of the effects of managed care on the intensity of outpatient substance abuse treatment. 
Conceptual Model 
Managed care firms use a variety of controls to ensure that substance abuse services provided in 
outpatient substance abuse treatment (OSAT) units are consistent with their own objectives. These 
managed care oversight mechanisms typically serve to control access to care and regulate the 
amount, type, or quality of care? Oversight mechanisms may include various forms of utilization 
review, treatment planning, precertification, or limits on the number of visits that may be provided. 
The scope of managed care oversight is defined as the extent or reach of oversight mechanisms 
in place in a provider organization. In some units, managed care oversight activities may affect only 
a small percentage of total clients. In other units, however, oversight activities apply to a large 
percentage of the client base. Furthermore, some units are required to respond to many different types 
of oversight including utilization review, specific treatment plans, and client follow-up, while in 
other units managed care firms employ fewer types of oversight activities. When more clients are 
covered by more managed care oversight requirements, OSAT units have fewer opportunities to set 
and maintain treatment practices without external influence and thus may be forced to reduce 
treatment intensity for managed care clients. This suggests Hypothesis 1: 
H 1: The greater the scope of managed care oversight, the lower is the intensity of outpatient substance 
abuse treatment. 
The stringency of managed care oversight refers to the level of constraints imposed by managed 
care oversight mechanisms on treatment providers. For example, when managed care firms place 
stringent rules on the number of visits authorized, providers have fewer alternatives regarding their 
responses to the requirements. When such oversight is less strict, however, providers have more 
opportunities to define compliance with demands and, therefore, maintain more discretion in 
responding to the external requirements. Although many managed care firms place limits on the 
number of visits that are authorized for payment, there is considerable variation in the number of 
visits authorized and in the potential responses of OSAT units. For example, OSAT providers facing 
stringent visit limits may continue to provide treatment services even though they are not being 
reimbursed for such care. OSAT units may be more likely to respond to managed care demands when 
visit limits are more stringent. This suggests Hypothesis 2: 
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H2: The greater the stringency of managed care oversight, the lower is the intensity of outpatient 
substance abuse treatment. 
Alternative Explanations 
Aspects of the market or environment, characteristics of the organization, and attributes of clients 
also may explain variation in client intensity to treatment among OSAT units; thus, they are potential 
alternative explanations to the hypothesized relationships between managed care scope, managed 
care stringency, and treatment intensity. 
Market forces and other environmental conditions could explain treatment intensity because they 
may force providers to demonstrate best practices or reduce treatment intensity in order to remain 
cost competitive. For example, in markets with greater health maintenance organization (HMO) or 
managed care penetration, units may not have access to clients and revenues from other, non- 
managed payers such as private pay or indemnity insurance. 
Treatment practices of OSAT units may be determined in part by the organization' s embeddedness 
in a larger administrative structure, its overall mission, and its approach to its markets. More 
specifically, the percentage of revenues covered by managed care and the number of managed care 
clients in the unit may indicate a greater dependence on managed care firms and may thus be 
associated with treatment intensity. 28 The uncertain nature of substance abuse treatment means that 
treatment practices are determined to a great extent by the treatment staff? 9-3° In addition, OSAT 
organizations are embedded in "complex networks consisting of state and federal agencies, 
professional associations and advocacy groups, and licensing and funding groups" and thus, 
accreditation status may be associated with treatment intensity. 3°(p638) 
Further, treatment organizations that are owned or managed by other organizations such as 
hospitals and mental health centers may exhibit different treatment practices than unaffiliated 
providers. Affiliated organizations may rely on larger, sponsoring organizations for scarce resources 
or to negotiate terms with resource providers on their behalf. 3~ Even when pressures from external 
actors are great, an organization may be more likely to resist external pressures that conflict with its 
mission. 32 Finally, because they may be committed to client needs regardless of external pressures, 
not-for-profit and public OSAT organizations may have differing responses to the demands of 
managed care firms regarding treatment intensity. 33 
The ongoing nature of methadone treatment services will lead to different levels of treatment 
intensity for methadone versus non-methadone units. Specifically, clients receiving methadone 
services are likely to remain in treatment longer and receive a different mix of individual and group 
treatment sessions over the course of treatment? 4 
Last, units treating clients with more severe or complex drug problems may exhibit greater 
treatment intensity because these clients require more treatment resources to address their needs. The 
model includes two control measures related to client mix: prior treatment for substance abuse and 
unemployment. 35-40 
Methods 
Sample and data collection 
This study uses data from the National Drug Abuse Treatment System Survey (NDATSS), a 
longitudinal program of research into the organizational structures, operating characteristics, and 
treatment modalities of outpatient substance abuse treatment units in the United States. In the 
NDATSS, an OSAT unit is formally defined as a physical facility with resources dedicated primarily 
(> 50%) to treating individuals with substance abuse problems (including alcohol and other drugs) 
on a non-residential basis. The sample was specifically designed to encompass the wide variety of 
organizations that comprise the nation's complex outpatient treatment system. OSAT units operated 
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by the military, the Department of Veterans Affairs, and those that target inmate populations in jails 
and prison settings are excluded from the survey population. 
A systematic random sample of OSAT units was selected for participation from the 1994 through 
1995 National Frame of Substance Abuse Treatment Programs (NFSATP), a national database of 
inpatient and outpatient substance abuse treatment programs compiled by the Institute for Social 
Research (ISR) at the University of Michigan in 1994. These units were combined with panel units 
that had been sampled as part of prior waves of NDATSS. In each wave, the sample is nationally 
representative and stratified by public/private status, treatment modality (methadone or non- 
methadone), and organizational affiliation (hospital, mental health center, other). After screening 
and non-response, the total number of organizations completing interviews in 1995 was 618, for a 
combined response rate of 85.6%. 
Several steps were taken during instrument development to validate interview items: extensive 
review of the managed care and substance abuse treatment research literature, site visits to several 
treatment units, and two pre-tests with nationally representative samples (n = 20 units) of each. 
Further, interviewers conducted in vivo checks on interview responses and used frequent probes and 
follow-up questions. In addition, study staff conducted internal consistency checks of key numbers 
(eg, numbers of clients) and, if necessary, called respondents back to clarify responses and address 
problems. In short, the study staff used telephone survey procedures that extensive research 41 
indicates will produce highly reliable and valid data. 
The director and clinical supervisor of each participating OSAT unit were asked to complete 
telephone interviews. Directors provided information concerning the unit's control status, environ- 
ment, finances, parent units, and managed care arrangements. Clinical supervisors provided 
information about staff, clients, treatment practices, and services provided. After the data were 
collected, extensive reliability checks were performed within each survey. Results also were 
compared between surveys to further confirm validity. These checks revealed very high levels of 
consistency in the NDATSS data? 2 
Data validity 
Research investigators have examined the validity of the data obtained from the NDATSS 
interviews by comparing these data to those of the Drug Services Research Study (DSRS), a national 
client-level investigation of drug treatment organizations. Specifically, data on treatment duration 
from 323 methadone treatment units in the 1990 NDATSS closely matched findings obtained from 
discharge abstracts from 520 outpatient methadone units in the 1990 DSRS. 43 
Measures 
Dependent variables 
Treatment intensity encompasses the length of treatment and the amount, or number, of sessions 
clients receive during treatment. While treatment intensity typically implies clinical services per unit of 
time, in this article the two components of the ratio are separated, allowing for a more precise 
understanding of the effects of managed care on both duration and amount of treatment. Specifically, 
treatment duration is operationalized as the average number of months in outpatient substance abuse 
treatment, a commonly used measure of treatment length. 44 The clinical supervisor of each OSAT unit 
reported the average number of months substance abuse clients received outpatient treatment in their 
unit. The amount of treatment is measured as the number of individual treatment sessions and group 
treatment sessions received over the entire course of treatment. The administrative director of each 
OSAT unit reported these variables in aggregate. Due to the skewed nature of the distribution of the three 
dependent variables, a natural log transformation of each was taken and used in the analyses. 
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Independent variables 
Scope of managed care oversight takes into account the degree to which six different oversight 
activities are in force in each OSAT unit. The measure is the sum of the percentages of total managed 
care clients for whom (1) managed care arrangements require written correspondence for 
precertification, (2) managed care arrangements specify the content of the ongoing treatment plan, 
(3) managed care arrangements specify that correspondence regarding authorization of sessions be 
conducted with a treatment staff member, (4) managed care arrangements require client follow-up 
by the treatment organization after discharge, (5) managed care arrangements require some limit on 
the number of authorized visits, and (6) managed care arrangements disallow claims after services 
have been provided. 
In the 1995 NDATSS, limiting the number of visits is the most prevalent form of managed care 
oversight. OSAT units reported that, on average, 73% of their managed care clients are subject to 
some type of visit limits from the managed care firm. Managed care firms also dictate the nature of 
the utilization review process. Specifically, OSAT units report that, on average, 34% of their 
managed care clients were subject to requirements that at least some of the utilization review 
correspondence be in writing, as compared with telephone calls to the managed care organization. 
Further, for over 56% of managed care clients managed care firms specify that utilization review 
correspondence must occur with a member of the treatment staff and not with clerical or adminis- 
trative personnel assigned to such activities. 
Managed care firms also are involved in the specification of the nature and type of treatment to 
be reimbursed. On average, OSAT units reported that managed care firms specify the content of 
treatment plans for 37% of managed care clients and require foUow-up with clients after discharge 
for 30% of all managed care cases. The use of sanctions was less prevalent among the 1995 NDATSS 
sample. OSAT units reported that managed care firms disallowed claims after treatment ended for 
an average 31% of managed care clients. 
Stringency of  managed care oversightis operationalized as a weighted average of the total number 
of visits authorized by managed care firms for the OSAT unit. The weighted average for each unit 
is based on questions that asked for the percentage of managed care clients with visit limits in four 
categories, ranging from those with limits greater than 20 visits to those with limits of five or fewer 
visits. The weights were assigned as follows: > 20 visits: weighted 1; 11 to 20 visits: weighted 2; 6 
to 10 visits: weighted 3; and < 5 visits: weighted 4. Thus, OSAT units with a higher weighted average 
have more clients with more stringent visit limits than units with a lower weighted average on this 
measure. In 1995, OSAT units reported that, on average, 19% of managed care clients had no visit 
limits, 39% had more than 20 visits authorized, 30% had 11 to 20 visits authorized, 11% had 6 to 10 
visits authorized, and 5% of the clients had the most stringent visit limits, with five or fewer OSAT 
visits authorized. 
Other definitions employed in this study are as follows: 
• HMO penetration in the market is measured as the percentage of the total county population 
enrolled in HMOs in 1995. The source for these data is a national database compiled by Sachs 
Group, Inc (Evanston, Illinois), a health care information farm. 
• Percentage ofrevenues covered by managed care is measured as the percentage of total OSAT 
unit revenues covered by various forms of managed care in 1995. 
• Number of  managed care clients is the number of OSAT clients covered by some form of 
managed care in 1995. 
• Professional staff is the percentage of total treatment staff with professional training. This 
concept is measured as the total treatment staff with master's or doctorate (MD, PhD) degrees 
divided by the total number of  treatment staff in each OSAT unit. 
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• J•intC•mmissi•n•nAccreditati•n•fHea•thcare•rganizati•ns(J•intC•mmissi•n)accredi- 
tation is a dummy variable indicating the units that are accredited by the Joint Commission. 
Units with such accreditation are coded 1; all other units are coded 0. 
• Unit affiliation is captured as whether the OSAT unit is free-standing or affiliated with a 
hospital or mental health center. Affiliation occurs if the unit is owned by, managed by, or 
affiliated with a hospital or mental health center. Such affiliations are measured by two dummy 
variables; free-standing or "other" affiliation is the referent category. 
• Ownership is expressed in three categories: private, not-for-profit; private, for-profit; and public. 
Two dummy variables are included in the model; public ownership is the referent category. 
• Methadone modality is measured by a single dummy variable. Units that offer methadone 
treatment are coded 1; all other units are coded 0. 
• Client mix is captured by two variables. Percentage of clients unemployed is measured as the 
percentage of all OSAT clients who were unemployed. Percentage of clients with some prior 
treatment is measured as the percentage of all OSAT clients who have received some prior 
treatment for substance abuse. 
Analysis strategy 
Descriptive analyses 
One aim of this article is to understand how various managed care activities are related to outpatient 
substance abuse treatment intensity. First, treatment intensity levels for all OSAT units in the NDATSS 
sample, as well as a comparison of treatment intensity for managed care and non-managed care units, 
are presented. Next, because methadone treatment units may have different levels of treatment intensity 
and different managed care activity, differences in treatment intensity for methadone units in managed 
care and methadone units not involved in managed care are investigated. 
Sample selection regression analyses 
Because all units did not report managed care activity, the managed care subsample may no longer 
be representative. It is possible that some form of selectivity occurs for OSAT units to become 
involved in managed care. Thus, the parameter estimates in an equation predicting treatment 
practices may be biased, inconsistent, and inefficient because the relationship between managed care 
participation and the treatment practice has not been taken into account. Generally, this problem is 
referred to as a sample selection problem. 45,46 
To address the issues related to sample selection, the effects of managed care on treatment duration 
are estimated using a two-equation maximum likelihood approach. 46 For each dependent variable, 
there are two sets of explanatory variables. One set, called the participation equation, explains 
whether or not OSAT units participate in managed care. A second set of  variables, the regression 
equation, explains the observed level of one of three measures of  treatment intensity. The predictors 
in the second set are only observed if an OSAT unit participates in managed care. The participation 




Unadjusted descriptive data suggest that there are differences in the treatment practices of units 
involved in managed care compared with those not involved in managed care. As shown in Table 1, the 
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T a b l e  1 
Treatment intensity for outpatient substance abuse treatment organizations (1995) comparing 
managed care (MC) and non-managed care, methadone and non-methadone units 
All MC Yes MC No 
(n = 618) (n = 236) (n = 382) 
Mean SD Mean SD Mean SD 
All units 
Months in treatment 9.78 12.97 7.84 10.19 10.98 14.32 
Individual treatment sessions 34.55 67.16 26.29 40.70 39.99 79.54 
Group treatment sessions 49.44 86.70 50.50 95.74 48.68 79.80 
All MC Yes MC No 
(n = 119) (n = 31) (n = 88) 
Mean SD Mean SD Mean SD 
Units providing methadone 
Months in treatment 
Individual treatment sessions 
Group treatment sessions 
23.50 22.50 20.52 21.04 24.58 23.01 
94.13 120.94 79.73 80.37 99.47 133.01 
69.74 103.02 89.01 147.14 60.84 74.33 
All MC Yes MC No 
(n = 485) (n = 200) (n = 285) 
Mean SD Mean SD Mean SD 
Units not providing methadone 
Months in treatment 6.20 4.58 5.81 4.65 6.47 4.52 
Individual treatment sessions 22.33 39.80 19.27 25.07 24.57 47.71 
Group treatment sessions 45.23 82.42 44.72 84.47 45.63 80.97 
SD, standard deviation 
average months in treatment for the entire sample of NDATSS units is 9.78 months. OSAT units with 
managed care have a shorter treatment duration (7.84 months) than those without managed care (10.98 
months). Further, the average number of individual treatment sessions over the course of treatment is 
34.55, and the average group sessions received over the course of treatment is 49.44. 
Units with managed care provide, on average, fewer total individual treatment sessions (26.29 
sessions versus 39.99 sessions) and about the same number of group treatment sessions than units 
without managed care (50.50 session versus 48.68 sessions). 
Treatment intensity: Managed care in methadone and non-methadone units 
Table 1 also shows treatment intensity for methadone and non-methadone units in the sample. On 
average, clients in methadone units experienced greater treatment intensity than clients in non- 
methadone units. Specifically, clients in methadone units stay an average of 23.5 months (compared 
with 6.2 for non-methadone units) and received 94.13 individual treatment sessions and 69.74 group 
sessions (compared with 22.33 individual sessions and 45.23 group sessions for clients in non- 
methadone units). When comparing treatment intensity for managed care versus non-managed care 
units, the pattern of findings described above generally holds within the methadone and the non- 
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methadone subsets. Specifically, clients in methadone units with managed care stayed for fewer 
months, received fewer individual treatment sessions, and received more group treatment sessions 
than clients in methadone units without managed care. Similarly, clients in non-methadone units with 
managed care experienced fewer months in treatment and fewer individual treatment sessions than 
clients in non-methadone, non-managed care units. There was no difference in the average group 
treatment sessions received over the course of treatment between managed care and non-managed 
care organizations that do not provide methadone services. In conclusion, differences in treatment 
intensity exist between units with managed care and units without managed care, and these 
differences hold for both methadone and non-methadone units in the sample. 
Managed  care 
Table 2 presents descriptive statistics and bivariate correlations for all main model variables. 
Results from this national sample of organizations indicate that 38% (n = 236) of  all OSAT 
organizations were involved in some form of managed care in 1995. Treatment units involved in 
managed care received, on average, 46% of their revenues from managed care arrangements and 
reported 191 clients covered by some form of managed care. 
Participation model: Effects on unit participation in managed care 
The participation model is discussed in detail in the appendix and descriptive data are provided 
(Table A-2). Table 3 presents the results of the sample selection regression. For two of the three 
dependent variables (months in treatment and individual treatment sessions received over the course 
of treatment), there is evidence of sample selection bias. For the model of group treatment sessions 
over the course of treatment, however, there appears to be no systematic selection effect. 
There axe two environmental characteristics in the model. The extent of competition shows a 
significant positive relationship in all three models, while the HMO penetration of the market is not 
systematically associated with managed care participation. 
In general, there are consistent patterns of relationships between organizational characteristics and 
unit involvement in managed care. In all three models, organizational size, the proportion of referrals 
from health care providers and employee assistance programs, and private ownership status (for-profit 
and not-for-profit) show significant, positive relationships with unit participation in managed care. By 
contrast, the methadone treatment modality shows a consistent, negative relationship with managed care 
participation in each of the three models. There is some evidence that hospital affiliation is positively 
associated with managed care participation in two models (months in treatment and group treatment 
sessions). Joint Commission accreditation status displays a marginally significant and positive 
relationship with managed care participation in the months in treatment and individual treatment 
session equations only. There are no significant relationships for two participation model predictors 
(HMO penetration in the market and affiliation with a mental health center). 
Main effects model: Managed care and treatment intensity 
After controlling for selection effects, as well as market, organization, and client characteristics, there 
is no significant relationship between the scope of managed care oversight and treatment intensity (see 
top section of Table 3). There is evidence, however, supporting the hypothesis that the stringency of 
managed care oversight activities is negatively associated with treatment intensity. Specifically, 
oversight stringency has a significant, negative relationship with the number of individual treatment 
sessions (p < .05) and number of group treatment sessions (p < .05) received over the course of treatment. 
The HMO penetration in the market has no significant relationship with months in treatment and 
number of individual treatment sessions. However, HMO penetration is marginally associated with 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table  3 
Results of sample selection regression 
Months treatment Individual sessions Group sessions 
(n = 557 units) (n = 559 units) (n = 559 units) 
Coeff SE Sig Coeff SE Sig Coeff SE Sig 
Main model 
Managed care oversight scope 0.001 0.003 0.003 0.003 0.000 0.003 
Managed care oversight 
stringency -0.003 0.002 -0.006 0.003 , -0.008 0.003 t 
HMO penetration (county) 0.005 0.005 -0.007 0.006 0.009 0.005 * 
No. of  managed care clients 0.000 0.000 0.000 0.000 -0.001 0.000 
Managed care revenues (%) 0.003 0.002 * 0.003 0.002 0.003 0.002 
Professional staff(%) 0.000 0.002 0.003 0.002 -0.005 0.002 t 
No. of licenses/accreditations -0.017 0.084 0.018 0.105 -0.082 0.092 
Mental health center affiliation j' -0.035 0.147 -0.254 0.181 -0.038 0.163 
Hospitalaffiliation ~' -0.180 0.153 -0.007 0.189 -0.118 0.166 
Private, for-profit ownership** 0.119 0.229 0.343 0.295 0.442 0.253 * 
Private, not-for-profit 
ownership** -0.011 0.162 0.322 0.203 0.303 0.183 
Methadone treatment modality tt 0.811 0.268 * 0.978 0.349 * 0.513 0.290 * 
Clients unemployed (%) 0.005 0.002 0.004 0.003 0.008 0.003 * 
Clients with prior treatment (%) -0.001 0.002 0.004 0.003 0.001 0.003 
Constant 1.040 0.379 * 1.226 0.492 , 3.125 0.410 
Participation model (probit) 
HMO penetration (county) -0.001 0.005 -0.002 0.005 0.001 0.005 
Competition 0.242 0.061 ~ 0.209 0.061 * 0.259 0.062 
Hospital affiliation 'j 0.359 0.213 * 0.256 0.207 0.369 0.217 * 
Mental health center affiliation" 0.197 0.151 0.129 0.151 0.176 0.152 
Size (FTE log) 0.348 0.076 ~ 0.351 0.071 ~ 0.346 0.078 
Methadone treatment modality tt -0.667 0.176 ~ -0.777 0.176 ~ -0.672 0.174 
Referrals HC providers~APs (%) 0.012 0.003 ~ 0.009 0.003 * 0.011 0.003 
Joint Commission accreditation ~§ 0.320 0.185 * 0.390 0.174 t 0.318 0.191 
Private for-profit ownership** 0.841 0.227 ~ 0.939 0.226 ~ 0.818 0.228 
Private, not-for-profit 
ownership** 0.317 0.153 t 0.345 0.154 t 0.335 0.153 , 
Constant -1.814 0.248 ~ -1.767 0.241 ~ -1.835 0.251 
Lambda 0.411 0.163 t 0.740 0.232 * -0.032 0.182 
Rho 0.506 0.725 -0.038 
*p< .10 
*p <.05 
*p < .01 
~p<.001 
~Dummy variable; referent category is other or no affiliation. 
**Dummy variable; referent category is public ownership. 
t'Dummy variable; referent is non-methadone treatment modality. 
~Dummy variable; referent category is no Joint Commission accreditation. 
Coeff, coefficient; SE, standard error; Sig, significance; HMO, health maintenance organization; FrE, full- 
time equivalent; HC, health care; EAPs, employee assistance programs; Joint Commission, Joint Commis- 
sion on Accreditation of Healthcare Organizations 
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the number of group treatment sessions (p < .  10). The number of managed care clients shows no 
significant relationship with treatment intensity. The percentage of revenues from managed care 
shows a marginal, positive relationship with months in treatment (p < .  10). 
Three additional organizational factors significantly influence treatment intensity. The percentage of 
total staff who are professionals displays a negative and significant relationship with the number of group 
treatment sessions (p < .05). Finally, private, for-profit ownership displays a marginally significant 
association with group sessions received over the course of treatment (p <.  10). 
There is consistent evidence that methadone units provide treatment that lasts longer and includes 
more individual and group treatment sessions. Specifically, the methadone status variable shows 
positive associations with the number of months in treatment (p < .01), individual treatment sessions 
(p < .01), and group treatment sessions (p < .10). One other client mix factor is associated with 
treatment intensity. The percentage of clients unemployed was found to be positively associated with 
group treatment sessions (p < .01). 
Additional analyses 
The primary goal of this study was to investigate the main effects of managed care oversight scope 
and stringency on substance abuse treatment intensity. Variation in the types of OSAT units in the 
sample and the degree to which units are involved in managed care, however, may suggest that the 
effects of managed care scope and stringency on treatment intensity may only hold under certain 
conditions. To explore other potential relationships, additional analyses were conducted. 
First, the possibility that the effects of managed care scope and stringency are conditional on the 
degree to which the OSAT unit is dependent on managed care was explored. Variables representing 
the interaction of (1) managed care oversight scope and percentage of revenues covered by managed 
care and (2) managed care oversight stringency and percentage of revenues covered by manageA care 
were created and tested. Significant effects of these interaction terms would suggest that the effects 
of managed care scope and stringency are conditional on the unit's dependence on managed care. No 
interaction terms were found to be significant. 
Next, the possibility that the effects of managed care oversight scope and stringency are different for 
clients covered by managed care versus clients not covered by managed care was examined. To address 
this possibility, the set of predictors was regressed on two measures of treatment intensity among 
managed care clients in each unit. The measures of treatment intensity were (1) the proportion of 
managed care clients remaining in treatment for 6 months or longer and (2) the proportion of managed 
care clients who received 20 or more treatment sessions over the course of treatment. Results obtained 
from generalized linear regression estimation are consistent with those reported for all clients. That is, 
findings suggest no systematic relationship between managed care oversight scope and treatment 
intensity for managed care clients. The stringency of managed care oversight, however, was negatively 
associated with both measures of treatment intensity among managed care clients. 
Last, the possibility that managed care has different effects on the intensity of treatment in 
methadone units and in non-methadone units was explored. Terms representing the interaction of (1) 
managed care oversight scope and methadone treatment status and (2) managed care oversight 
stringency and methadone treatment status were created and tested. Significant effects of these 
interaction terms would suggest that the effects of managed care scope and stringency are conditional 
on whether or not the unit provided methadone treatment services. Only one of the six interaction 
terms was found to be significant. The term representing methadone treatment and managed care 
oversight scope was significant in the model estimating the number of group sessions provided over 
the course of treatment. Specifically, managed care oversight scope has a significant negative effect 
on group treatment sessions in methadone units. This effect, however, does not hold for non- 
methadone units. No other interaction terms for methadone and managed care oversight were found 
to be significant. 
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Implications for Behavioral Health Services 
Managed care selection 
This study provides evidence that managed care influences outpatient substance abuse treatment 
through the process by which units are selected by managed care firms or choose to participate in 
managed care programs. In other words, treatment intensity is systematically related to whether or 
not the OSAT unit participates in managed care. Specifically, units that participate in managed care 
have shorter treatment duration and provide fewer individual sessions over the course of treatment. 
While selection bias has been accounted for in this examination of the effects of managed care 
oversight on treatment intensity, the implications of such systematic selection also must be 
addressed. On one hand, the selection of high-quality, efficient organizations for managed care 
participation could ultimately improve the overall treatment system. As less efficient, lower-quality 
organizations are left out of managed care programs, they may be unable to survive. Their exit would 
leave a more efficient, high-quality system of providers. On the other hand, if specific types of 
treatment organizations are excluded by (or choose not to participate in) managed care, such as public 
units, methadone treatment providers, small units, and those that are not owned or managed by 
another organization, this may create critical access issues for those in need of substance abuse 
treatment. In sum, the process by which treatment organizations choose to participate in (or are 
chosen for) managed care programs is not random and has implications for substance abuse treatment 
processes, and ultimately, the nation's treatment system. 
Managed care oversight 
Results from these analyses suggest that there are differences in the levels of treatment intensity 
between OSAT units involved in managed care and those not involved in managed care. After 
controlling for managed care selection, as well as several environmental and organizational 
characteristics, the scope of managed care oversight does not influence treatment intensity in any 
systematic fashion. C~eater managed care oversight stringency, however, shows a clear, negative 
association with treatment intensity in OSAT units. 
Managed care firms and treatment organizations dedicate significant resources to oversight 
activities, including preauthorization, utilization review, treatment planning, ongoing correspon- 
dence, and post-treatment review. While the scope of managed care oversight does not directly 
influence treatment intensity, it is important to consider that managed care oversight may have other 
effects on OSAT units. For example, OSAT units may incur substantial costs as they handle the many 
diverse oversight requirements of managed care. In addition, when oversight activities apply to a 
greater percentage of clients, OSAT units may incur other nonfinancial costs including increased 
frustration of staff and increased confusion for clients. Managed behavioral care programs may be 
better served by doing away with direct behavioral control in favor of other ways of managing care 
and costs, such as careful review and selection of providers and the use of capitated payment schemes. 
This article presents evidence that OSAT providers are forced to change accepted treatment 
practices when managed care firms exert stringent visit limits, thus confirming a widely held belief 
that constraints imposed by managed care lead to less intense substance abuse treatment. The study 
also finds that managed care oversight limits treatment intensity in both methadone and non- 
methadone settings. Oversight stringency may be more effective than oversight scope in influencing 
treatment because it involves more direct sanctions or penalties for noncompliance. Thus, if visits 
are provided beyond those authorized by managed care firms, OSAT units are not reimbursed for the 
services provided in those visits. This greater degree of enforcement, vigilance, and sanctions may 
increase organizational compliance. 32 
The finding that greater stringency is effective in reducing treatment intensity has several 
important implications for managed care policy. Historically, visit limits were often determined in 
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at least two ways in managed care programs. First, visit limits for substance abuse services are often 
part of the benefit design in managed behavioral care. While specific plans vary substantially, 
managed behavioral care benefit packages typically include specific limits on the number of 
substance abuse sessions that are covered by the plan in a 12-month period. 48 Second, managed care 
firms restrict visits through preauthorization and various forms of concurrent and post-discharge 
utilization review. The number of visits in the benefit package is often described as "theoretical 
visits" because the actual number of visits that will be reimbursed is determined through ongoing 
correspondence between OSAT staff and the managed care firm. This study provides clear evidence 
that more stringent limits constrain drug treatment intensity. These findings should be considered as 
new public and private managed care programs are developed and also as new federal guidelines are 
established. For example, this study provides empirical support for some managed care oversight 
activities that are currently being developed and implemented by some managed behavioral care 
plans, including the use of medical necessity criteria to determine the number of sessions covered, 
rather than using arbitrary visit limits. 
Taking a more comprehensive approach to substance abuse treatment oversight is important. If  
visit limits are too severe, clients will have reduced opportunities to achieve positive treatment 
outcomes. As new managed care policies and programs are developed, efforts should also be made 
to include coverage for additional types of services, including aftercare and other services that may 
achieve desired treatment outcomes even though clients may have fewer face-to-face therapy visits. 
Limitations 
The NDATSS is a comprehensive, ongoing body of research on OSAT organizations and thus 
includes aggregate data reported by the administrative and clinical leaders of outpatient treatment 
facilities. It is important to note that unit directors provide estimates of treatment intensity for the 
entire population of clients served in the organization. Despite the fact that study results compare 
favorably with data reported from client-level research, it is possible that the estimates made by unit 
directors may differ from actual lengths of stay and the number of treatment sessions received by 
clients. Further, the data do not permit an analysis of how managed care oversight and treatment 
intensity are associated with treatment outcomes for individual substance abuse treatment clients. 
Without client-specific data, this research cannot demonstrate how shorter, less intense treatment 
may affect various post-treatment outcomes. Nevertheless, this study provides an important 
organizational-level perspective on the relationships between managed care and treatment duration. 
Further research is needed to clearly identify and measure specific relationships between managed 
care oversight, treatment intensity, and various treatment outcomes. 
Conclusion 
Managed care holds both the promise of improving the drug treatment system and the potential 
of limiting treatment services. This study provides important insights into what happens at the 
intersection of these two societal trends. Further work is needed, however, to understand more 
specifically how providers deal with conflicting demands regarding treatment practices and, 
ultimately, how these demands influence the effectiveness of substance abuse treatment. This 
investigation lays the groundwork for future research that may increase our understanding of the role 
of managed care in a comprehensive solution to the consequences of addiction. 
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Appendix A 
Participation Model 
This appendix provides details of the participation model used in the sample selection analyses. 
The conceptual model suggests that outpatient substance abuse treatment (OSAT) unit participation 
in managed care will be a function of several environmental and organizational characteristics. The 
full details of the model have been presented elsewhere. 47 The hypothesized relationships between 
organizational and environmental characteristics and unit participation in managed care were 
developed from previous research z8,33,49.5° and are summarized in Table A-1. In addition, measure- 
ment of study variables is described. Descriptive statistics and bivariate correlations for participation 
model variables are shown in Table A-2. 
M e ~ u r e m e ~  
The following variables are included only in the participation equation. All other participation 
equation Variables are included in the main model regression and have been described in the body 
of this article. 
Managed care participation--The dependent variable in the participation equation is a 
categorical variable that is equal to 1 for those OSAT organizations that reported that more than 
10 OSAT clients were covered by managed care arrangements during the most recent complete 
fiscal year. 
Competition--This variable is measured by a factor score that was created using principal 
components factor analysis (regression method). Two distinct factors emerged in the analysis 
of 10 different items dealing with competition of the OSAT unit. One of the two factor scores 
is included, competition for costs, which is based on five items measuring the degree of 
competition for the cost of treatment to clients, the costs of treatment to payment sources other 
than clients, marketing efforts, pricing strategies, and cost control strategies. 
Table A - 1  
Variable and suggested relationship with unit participation in managed care 
Variable Relationship 
Managed care penetration in market 
Competition 
Affiliation with a hospital 
Affiliation with a mental health center 
Larger size 
Methadone treatment modality 
Referrals from health care organizations/employee assistance programs 
Joint Commission accreditation 
Private, for-profit ownership 







































































































































































































































































































































































































































































































































































































































































































































































































• Referrals from health care organizations and employee assistance programs--The clinical 
supervisor of each OS AT unit reported the percentage of clients referred by a variety of referral 
sources. The percentages from four categories of referral sources that reflect provider 
organizations and those most likely to be involved in managed care (substance abuse treatment 
facilities, mental health agencies, hospitals/physicians/general health care providers, and 
employee assistance programs) were summed to create one measure of the overall percentage 
of client referrals from providers or managed care-related organizations. 
• Joint Commission accreditationmThis variable is used as a proxy measure of organizational 
quality. Units with Joint Commission accreditation were coded 1; all other units were coded 0. 
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